Unicycive Therapeutics

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update

Data highlights the potential safety and reno-protective effect of UNI-494 Data highlights the potential safety and reno-protective effect of UNI-494

Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress

Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones

Unicycive Announces Full Year 2022 Financial Results and Provides Business Update

Bed Bath & Beyond

Tenax Therapeutics

Use these tips for analyzing penny stocks after a market crash The post Analyzing Penny Stocks After a Market Crash, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Analyzing Penny Stocks After a Market Crash, 3 Tips

FuelCell Energy

Troika Media Group

Use these tips for future proofing your penny stocks strategy The post How to Future Proof Your Penny Stocks Investing Strategy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Future Proof Your Penny Stocks Investing Strategy

Virax Biolabs Group Ltd

What you need to know about day trading penny stocks The post Penny Stocks Investing: The Pros and Cons of Day Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Investing: The Pros and Cons of Day Trading

Novo Integrated Sciences, Inc.

Use these tips for trading penny stocks during market uncertainty The post Penny Stocks Trading: Tips for Market Uncertainty  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Trading: Tips for Market Uncertainty

$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

Data from two abstracts supporting UNI-494's potential to treat acute and chronic kidney injury accepted for presentation at the 28 th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT 2023 Conference

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

Develops Renazorb opportunity in new market for patients with hyperphosphatemia

Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

Data support UNI-494's potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia Data support UNI-494's potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation's Spring Clinical Meetings

Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the termination of its “at-the-market” equity offering program (the “ATM Offering”) with JonesTrading Institutional Services, LLC as sales agent. The Company elected to terminate the ATM Offering to limit uncertainty and unfavorable dilution for its shareholders.

Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023 Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

ORLANDO, FL / ACCESSWIRE / December 9, 2022 / RedChip Companies will air a new interview with Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 10, at 7 p.m. Eastern Time (ET).

Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction

Unicycive to Participate in Upcoming Investor Conferences

Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA)

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis

Unicycive Announces Third Quarter Financial Results and Provides Business Update

Multiple Data Presentations Support the Company's Pipeline of Innovative Product Candidates aimed at Improving the Quality-of-Life for Patients Battling Kidney Disease

Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology's Kidney Week 2022

Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction

Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Data support the Company's pipeline of innovative product candidates aimed at improving the quality-of-life for patients battling kidney disease Data support the Company's pipeline of innovative product candidates aimed at improving the quality-of-life for patients battling kidney disease

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology's Kidney Week 2022

On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023

Unicycive Announces Second Quarter Financial Results and Provides Business Update

Hyperphosphatemia ranked as area of greatest unmet need

Unicycive Reports Key Findings from Independent Renal Dietitian Survey

Renazorb product profile rated as best-in-class phosphate binder

News for Unicycive Therapeutics Stock (UNCY)